Advertisement

Alcohol Septal Ablation

Chapter

Abstract

Hypertrophic obstructive cardiomyopathy (HOCM) is a relatively common genetic disorder that exhibits wide variability in its clinical expression. Symptomatic patients most frequently experience exertional dyspnea, chest pain, fatigue and, occasionally, orthopnea or nocturnal dyspnea. Five to 10 % of symptomatic patients with HOCM are refractory to medical therapy (typically beta blockers and heart rate lowering calcium antagonists) and may require mechanical approaches targeting relief of obstruction and mitral regurgitation. Previously, mechanical approaches were limited to surgical myectomy, however, since the late 1990s increasing experience with a percutaneous technique, alcohol septal ablation, has become a widely-used alternative to surgical myectomy.

Keywords

Pacemaker Heart failure Cardiac resynchronization 

References

  1. 1.
    Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:452–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He Z-X, Verani M, Roberts R, Spencer WH. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Kober L, Endresen K, Eriksson MJ, Jorgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. A Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4:256–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Sorajja P, Ommen SR, Holmes DR, Dearani JA, Rihal CS, Gersh BJ, LennonRJ NRA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, Nielsen C, Leya F, Buergler JM, Rowe SK, Woo A, Munoz Maldonado Y, Spencer III WH. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American registry. J Am Coll Cardiol. 2011;58:2322–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, Bundgaard H. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99:1012–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2017

Authors and Affiliations

  1. 1.Associate Professor of Medicine, Division of CardiologyTufts Medical Center, Tufts University School of MedicineBostonUSA

Personalised recommendations